| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T83797 | ||||
| Target Name | Hepatocyte growth factor (HGF) | ||||
| Type of Target |
Clinical trial |
||||
| Action against Disease Model | Rilotumumab | Drug Info | Enhances temozolomide- and docetaxel-induced anti-proliferative effects in U87-MG cells in vitro; Increases docetaxel-induced apoptosis in U87-MG in vitro;Enhances temozolomide-and docetaxel-induced anti-growth effects in U87-MG xenografts | [1] | |
| References | |||||
| REF 1 | Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008 Jun;7(6):504-16. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.